SG10201407640PA - Hepatitis b virus specific antibody and uses thereof - Google Patents

Hepatitis b virus specific antibody and uses thereof

Info

Publication number
SG10201407640PA
SG10201407640PA SG10201407640PA SG10201407640PA SG10201407640PA SG 10201407640P A SG10201407640P A SG 10201407640PA SG 10201407640P A SG10201407640P A SG 10201407640PA SG 10201407640P A SG10201407640P A SG 10201407640PA SG 10201407640P A SG10201407640P A SG 10201407640PA
Authority
SG
Singapore
Prior art keywords
hepatitis
specific antibody
virus specific
fragment
antibody
Prior art date
Application number
SG10201407640PA
Inventor
Antonio Bertoletti
Sastry Konduru Seetharama
Paul Anthony Macary
Soh Ha Chan
Chien Tei Too
Original Assignee
Agency Science Tech & Res
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Univ Singapore filed Critical Agency Science Tech & Res
Priority to SG10201407640PA priority Critical patent/SG10201407640PA/en
Publication of SG10201407640PA publication Critical patent/SG10201407640PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

50 There is provided at least one isolated antibody or fragment thereof, wherein the antibody or fragment thereof is capable of specifically binding to at least one HBV derived peptide. 5 Fig. 1
SG10201407640PA 2009-11-19 2010-11-19 Hepatitis b virus specific antibody and uses thereof SG10201407640PA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201407640PA SG10201407640PA (en) 2009-11-19 2010-11-19 Hepatitis b virus specific antibody and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26290609P 2009-11-19 2009-11-19
SG2010044576A SG177025A1 (en) 2010-06-21 2010-06-21 Hepatitis b virus specific antibody and uses thereof
SG10201407640PA SG10201407640PA (en) 2009-11-19 2010-11-19 Hepatitis b virus specific antibody and uses thereof

Publications (1)

Publication Number Publication Date
SG10201407640PA true SG10201407640PA (en) 2014-12-30

Family

ID=54193680

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2010044576A SG177025A1 (en) 2009-11-19 2010-06-21 Hepatitis b virus specific antibody and uses thereof
SG10201407640PA SG10201407640PA (en) 2009-11-19 2010-11-19 Hepatitis b virus specific antibody and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2010044576A SG177025A1 (en) 2009-11-19 2010-06-21 Hepatitis b virus specific antibody and uses thereof

Country Status (5)

Country Link
US (1) US9334317B2 (en)
EP (1) EP2501723B1 (en)
CN (1) CN102781961A (en)
SG (2) SG177025A1 (en)
WO (1) WO2011062562A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6837840B2 (en) * 2014-01-24 2021-03-10 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Binding protein and how to use it
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7038703B2 (en) * 2016-09-23 2022-03-18 ライオン ティーシーアール ピーティーイー．エルティーディー． HBV antigen-specific binding molecule and fragments thereof
CN107880118B (en) * 2017-10-12 2018-10-19 南京京达生物技术有限公司 A kind of hepatitis B virus core antigen detection IgG antibody and application
CN110156889B (en) * 2018-02-14 2023-03-10 中国科学院广州生物医药与健康研究院 High affinity HBs T cell receptor
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
US20210015869A1 (en) 2018-04-05 2021-01-21 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
AU2019318560A1 (en) 2018-08-09 2021-02-25 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
WO2020053742A2 (en) * 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
US20220050114A1 (en) 2018-09-11 2022-02-17 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
US20210292413A1 (en) * 2018-09-25 2021-09-23 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
WO2020223535A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
KR20220032568A (en) 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 FLT3L-FC fusion protein and methods of use
CN112409474B (en) * 2019-08-23 2023-02-28 香雪生命科学技术（广东）有限公司 High-affinity TCR (T cell receptor) for identifying SSX2 antigen
JP7494199B2 (en) * 2019-09-27 2024-06-03 富士レビオ株式会社 Immunoassay for hepatitis B virus core-related antigen and kit therefor
BR112022005687A2 (en) 2019-09-30 2022-06-21 Gilead Sciences Inc Vaccines against hbv and methods to treat hbv
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN113138276B (en) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 Method for detecting HBcAg and antibody
AR121620A1 (en) 2020-03-20 2022-06-22 Gilead Sciences Inc 4-C-SUBSTITUTED-2-HALO-2-DEOXIADENOSINE NUCLEOSIDE PRODRUGS AND METHODS OF PREPARATION AND USE THEREOF
JP2023531531A (en) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
WO2022032404A1 (en) * 2020-08-13 2022-02-17 Envases Chiloe S.A. Arrangement of expanded polystyrene (eps) boxes grouped in a tower on a pallet
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
KR20240006683A (en) 2021-05-13 2024-01-15 길리애드 사이언시즈, 인코포레이티드 Combination of TLR8 modulating compounds and anti-HBV siRNA therapeutics
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (en) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117624340B (en) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 T Cell Receptor (TCR) recognizing human Hepatitis B Virus (HBV) antigen and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5972656A (en) 1989-03-14 1999-10-26 Bionebraska, Inc. Mercury binding polypeptides and nucleotides coding therefore
EP0698042A1 (en) * 1993-05-10 1996-02-28 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis Composition of antibodies against hepatitis b surface antigen
US6417324B1 (en) 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
US20040156861A1 (en) 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
ME02705B (en) 2005-08-31 2017-10-20 Merck Sharp & Dohme Engineered anti-il-23 antibodies

Also Published As

Publication number Publication date
EP2501723A4 (en) 2013-04-17
US9334317B2 (en) 2016-05-10
EP2501723A1 (en) 2012-09-26
WO2011062562A1 (en) 2011-05-26
EP2501723B1 (en) 2017-06-28
SG177025A1 (en) 2012-01-30
US20120308580A1 (en) 2012-12-06
CN102781961A (en) 2012-11-14

Similar Documents

Publication Publication Date Title
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
NZ628206A (en) Virus like particle composition
SG179566A1 (en) Hcv protease inhibitors
MX2011012060A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide.
HK1138297A1 (en) Human antibodies against hepatitis c virus (hcv) uses thereof (hcv)
ZA201003509B (en) Hepatitis c virus antibodies
WO2006131936A3 (en) Hepatitis c virus vaccine
MX2011011925A (en) Tri- or tetraspecific antibodies.
WO2012058308A3 (en) Antibody based reagent that specifically recognizes toxic oligomeric form of beta-amyloid
PL1913138T3 (en) Processes for the manufacture of pancreatin powder with low virus content
GB0718984D0 (en) Structure of the hepatitis C virus NS5A protein
MX344040B (en) Improved antibodies of the class igg4.
TW200833678A (en) HCV protease inhibitorscross reference
MD4589C1 (en) Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
NZ593297A (en) Myostatin binding proteins
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2009048839A3 (en) Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
IL212040A0 (en) Hepatitis c antibodies and uses thereof
MX2010006313A (en) Viral polymerase inhibitors.
WO2009067191A3 (en) Methods and compositions for the treatment of hepatitis c virus (hcv) infection
MY161868A (en) Anti-bv8 antibodies and uses thereof
MX2010005701A (en) Method for producing vaccinal viral strain of a virus of the reoviridae family.
MX2011006516A (en) Hepatitis c virus combination therapy.
WO2009148229A3 (en) Immunogenic peptide and composition containing the peptide for preventing or treating hpv-related diseases